BioCentury
ARTICLE | Clinical News

Luseogliflozin: Phase III data

October 21, 2013 7:00 AM UTC

The open-label, Japanese Phase III Study-2 in 299 Type II diabetics showed that once-daily oral luseogliflozin met the primary endpoint of reducing HbA1c at week 52 compared to baseline (0.5% reductio...



Access The Full Article